Skip to content
OpenCapital
Get started

Avalo Therapeutics AVTX Q4 2025 Annual earnings

Reported March 23, 2026 · Before market open

Revenue$59.0KIn lineDiluted EPS-$0.37Beat by $1.17
Revenue estimate$59.0K
EPS estimate-$1.54

Next report

Aug 6, 2026 (In 3 weeks)
EPS estimate-$0.66

Financials

Q4 2025

Income statement

See full
Revenue$59.0K-69.3%
Operating income-$19.7M-48.3%
Net income-$13.7M+61.2%
EPS (diluted)-$0.37—

Balance sheet

See full
Cash & equivalents$16.1M-88.0%
Total debt$427.0K-53.5%
Total equity$83.0M-37.6%
Total assets$116.5M-22.7%

Cash flow

See full
Operating cash flow-$14.2M+5.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$329.31M+324%
Enterprise value$313.63M+660%

Returns & leverage

See full
Return on equity-72.4%+58.5pp
Debt / equity0×0.0×
Current ratio8.1×-11.8×

Versus estimates

Revenue

Q4 2025$59.0KIn line
Q4 2024$192.0K

Diluted EPS

Q1 2026-$0.98Beat by $0.02
Q4 2025-$0.37Beat by $1.17
Q3 2025-$2.19Miss by $0.52Q2 2025-$1.92Miss by $0.49Q1 2025-$1.25Miss by $0.18Q4 2024-$7.95Miss by $8.53

Ask the moment Avalo Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Avalo Therapeutics report Q4 2025 earnings?
Avalo Therapeutics (AVTX) reported Q4 2025 earnings on March 23, 2026 before market open.
What were Avalo Therapeutics's Q4 2025 revenue and EPS?
Avalo Therapeutics reported revenue of $59.0K and diluted EPS of $-0.37 for Q4 2025.
Did Avalo Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $59.0K by -. EPS beat the consensus estimate of $-1.54 by $1.17.
How did Avalo Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 69.3% from $192.0K a year earlier and diluted EPS grew 95.3% from $-7.95.
Where can I find Avalo Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001534120-26-000010) and the 10-K periodic report (0001534120-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.